☆ 4.7 Editorial Material

NO RELAPSE OF NEUROMYELITIS OPTICA DURING DRUG-INDUCED B-LYMPHOPENIA WITH HYPOGAMMAGLOBULINEMIA

NEUROLOGY (2010)

Journal

NEUROLOGY

Volume 75, Issue 19, Pages 1745-1747

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1212/WNL.0b013e3181fc2788

Keywords

-

Categories

Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Clinical Neurology

Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation

Rui Li, Cong Li, Qiao Huang, Zifeng Liu, Jingjing Chen, Bingjun Zhang, Chunxin Liu, Yaqing Shu, Yuge Wang, Allan G. Kermode, Wei Qiu

Summary: The optimal duration of immunosuppressant treatment and the risk of discontinuation for neuromyelitis optica spectrum disorder (NMOSD) were explored in this study. Long-term use of immunosuppressant medication is generally suitable for NMOSD, but there is a higher risk of relapse after discontinuation, especially for patients with longitudinal extensive transverse myelitis.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Treatment of Neuromyelitis Optica Spectrum Disorders

Koon-Ho Chan, Chi-Yan Lee

Summary: NMOSD is an autoimmune disorder that predominantly affects females, leading to serious CNS inflammatory disorders. The pathogenesis involves AQP4-IgG autoantibodies targeting aquaporin-4, triggering astrocytopathy and neuroinflammation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Immunology

Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder

Chen Du, Pei Zeng, Jin-Rui Han, Tian-Xiang Zhang, Dongmei Jia, Fu-Dong Shi, Chao Zhang

Summary: The study showed that tocilizumab in combination with high-dose methylprednisolone was effective in reducing disability and relapse risk in patients with acute myelitis.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Risk Factors and Nomogram for Predicting Relapse Risk in Pediatric Neuromyelitis Optica Spectrum Disorders

Shanchao Zhang, Shan Qiao, Haiyun Li, Ranran Zhang, Meiling Wang, Tao Han, Xuewu Liu, Yunshan Wang

Summary: This study aimed to investigate the risk factors for relapses in Chinese children with NMOSD, and to establish a risk score model and a predictive nomogram to help clinicians predict relapse risk and provide personalized treatment. The results showed that discharge EDSS score, mixed-lesion onset, counts of concomitant autoantibodies, and maintenance therapy were independent factors for relapse. The risk score model and predictive nomogram demonstrated good accuracy in predicting relapse. This study is of significant clinical importance for predicting relapse risk in children with NMOSD.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Clinical Neurology

Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report

Sophie Chatterton, John Douglas Edward Parratt, Karl Ng

Summary: Eculizumab has been shown to be effective in maintaining disease remission in NMOSD patients who are AQP4-IgG seropositive. The utility of eculizumab in treating acute episodes of NMOSD is under review, but it may potentially aid recovery from severe attacks and minimize disability accrual.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Neurosciences

BLK polymorphisms and expression level in neuromyelitis optica spectrum disorder

Bo-Wen Yin, Bin Li, Arshad Mehmood, Congcong Yuan, Shuang Song, Ruo-Yi Guo, Lu Zhang, Tianzhao Ma, Li Guo

Summary: This study found that the minor allele G of rs2248932 in the BLK gene is associated with reduced susceptibility to NMOSD and provides protection for AQP4-positive patients. BLK mRNA expression levels were lower in NMOSD patients compared to healthy controls, but significantly higher in acute-untreated patients.

CNS NEUROSCIENCE & THERAPEUTICS (2021)

Add to Collection

Review Immunology

Immuno-pathogenesis of neuromyelitis optica and emerging therapies

Norio Chihara, Takashi Yamamura

Summary: Neuromyelitis optica (NMO) is an inflammatory disease similar to multiple sclerosis (MS), characterized by relapsing optic neuritis and myelitis. Autoantibodies against NMO play a crucial role in the inflammatory pathology involving proinflammatory cytokines and various inflammatory cells. Recent clinical trials have shown the efficacy of specific antibodies in preventing NMO relapses.

SEMINARS IN IMMUNOPATHOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Decreased kynurenine in cerebrospinal fluid and potential role in neuromyelitis optica spectrum disorder

Fuhua Peng, Hongda She, Yuge Wang, Li Xu, Yilong Shan, Yanyu Chang, Xiaonan Zhong, Rui Li, Wei Qiu, Yaqing Shu, Sha Tan

Summary: This pilot study found that abnormal tryptophan metabolism occurs in NMOSD patients and kynurenine might be a potential target for the treatment of AQP4-IgG-positive NMOSD patients.

JOURNAL OF NEUROCHEMISTRY (2023)

Add to Collection

Article Immunology

Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder

Yasunobu Hoshino, Daisuke Noto, Shuhei Sano, Yuji Tomizawa, Kazumasa Yokoyama, Nobutaka Hattori, Sachiko Miyake

Summary: This study demonstrates that B cells in patients with NMOSD are abnormally skewed towards antibody-secreting cells at the transcriptome level during the early differentiation phase, and IL-2 might participate in this pathogenic process. CD25(+) naive B cells are identified as a novel candidate precursor of antibody-secreting cells in autoimmune diseases.

JOURNAL OF NEUROINFLAMMATION (2022)

Add to Collection

Article Immunology

Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report

Weihe Zhang, Yujuan Jiao, Jinsong Jiao, Ming Jin, Dantao Peng

Summary: We report a case of elderly-onset NMOSD with mutant FCGR3A genotype who was successfully treated with ofatumumab after multiple relapses, showing good response and tolerability.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder

Wei Lin, Chung-Hsing Chou, Fu-Chi Yang, Chia-Kuang Tsai, Yu-Kai Lin, Yueh-Feng Sung

Summary: A patient previously diagnosed with RRMS experienced fatal rebound syndrome after cessation of fingolimod treatment. Fingolimod withdrawal syndrome, although more commonly seen in patients with MS, can also occur in other patients.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Clinical Neurology

Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis

Ziqian Yin, Youjia Qiu, Aojie Duan, Ting Fang, Zhouqing Chen, Jiang Wu, Zhong Wang, Gang Chen

Summary: This network meta-analysis compared the efficacy and tolerability of monoclonal antibodies and immunosuppressants in treating NMOSD. The results showed that rituximab had the highest reduction in annualized relapse rate, while tocilizumab had the best performance in reducing relapse rate. MMF and rituximab had fewer adverse events compared to other interventions.

JOURNAL OF NEUROLOGY (2023)

Add to Collection

Article Immunology

CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage

Jae-Won Hyun, Yeseul Kim, Ki Hoon Kim, Su-Hyun Kim, Mads Nikolaj Olesen, Nasrin Asgari, Sasitorn Siritho, Friedemann Paul, Ho Jin Kim

Summary: This study investigated whether double seronegative NMOSD (DN-NMOSD) and NMOSD with AQP4 antibody (AQP4-NMOSD) share the same underlying pathophysiology. The results suggest that DN-NMOSD has a different underlying pathogenesis compared to AQP4-NMOSD.

JOURNAL OF NEUROINFLAMMATION (2022)

Add to Collection

Article Clinical Neurology

Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders A 14-Year Real-Life Experience

Su-Hyun Kim, Na Young Park, Ki Hoon Kim, Jae-Won Hyun, Ho Jin Kim

Summary: This study investigated the frequency and predictors of hypogammaglobulinemia during long-term rituximab (RTX) treatment in patients with neuromyelitis optica spectrum disorder (NMOSD) and its association with infections. The results showed that the mean serum immunoglobulin G (IgG) level declined significantly after 2 years of treatment and continued to decline at a rate of 2%-8% per year for the following 8 years. The proportion of patients with hypo-IgG (<6 g/L) increased from 1.2% after 1 year of treatment to 41% after 14 years of treatment. The risk factors for hypo-IgG included treatment duration, mean annual RTX dose, history of mitoxantrone, hypo-IgG at baseline, and body mass index >25 kg/m². However, the reduced immunoglobulin levels were not associated with an increased incidence of infections.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Add to Collection

Article Clinical Neurology

Deep learning-based relapse prediction of neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody

Liang Wang, Lei Du, Qinying Li, Fang Li, Bei Wang, Yuanqi Zhao, Qiang Meng, Wenyu Li, Juyuan Pan, Junhui Xia, Shitao Wu, Jie Yang, Heng Li, Jianhua Ma, Jingzi ZhangBao, Wenjuan Huang, Xuechun Chang, Hongmei Tan, Jian Yu, Lei Zhou, Chuanzhen Lu, Min Wang, Qiang Dong, Jiahong Lu, Chongbo Zhao, Chao Quan

Summary: This study confirmed the superiority of deep learning in designing a predictive model for relapse in patients with AQP4-ab-positive NMOSD, with the LogisticHazard model showing the best predictive power in validation.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Oncology

Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma

Hirotaka Shoji, Sachiyo Yoshio, Yohei Mano, Hiroyoshi Doi, Masaya Sugiyama, Yosuke Osawa, Kiminori Kimura, Taeang Arai, Norio Itokawa, Masanori Atsukawa, Yoshihiko Aoki, Moto Fukai, Akinobu Taketomi, Masashi Mizokami, Tatsuya Kanto

INTERNATIONAL JOURNAL OF CANCER (2017)

Add to Collection

Article Multidisciplinary Sciences

Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model

Yuko Tokunaga, Yosuke Osawa, Takahiro Ohtsuki, Yukiko Hayashi, Kenzaburo Yamaji, Daisuke Yamane, Mitsuko Hara, Keisuke Munekata, Kyoko Tsukiyama-Kohara, Tsunekazu Hishima, Soichi Kojima, Kiminori Kimura, Michinori Kohara

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Reduced therapeutic effect of antiviral drugs in patients with hepatitis B virus reactivation after hematopoietic stem cell transplantation

Masamichi Kimura, Koji Nishikawa, Hisashi Sakamaki, Masashi Mizokami, Kiminori Kimura

HEPATOLOGY RESEARCH (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs

Koji Nishikawa, Yosuke Osawa, Kiminori Kimura

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Long-awaited treatment for hepatitis C virus decompensated cirrhosis

Kiminori Kimura

JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Biophysics

A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation

Koji Nishikawa, Kiminori Kimura, Yoshinobu Kanda, Masaya Sugiyama, Kazuhiko Kakihana, Noriko Doki, Kazuteru Ohashi, Sung Kwan Bae, Kazuhiro Takahashi, Yuko Ishihara, Ishikazu Mizuno, Yasushi Onishi, Masahiro Onozawa, Makoto Onizuka, Masahide Yamamoto, Tetsuya Ishikawa, Kazuaki Inoue, Shigeru Kusumoto, Satoshi Hashino, Hidetsugu Saito, Tatsuya Kanto, Hisashi Sakamaki, Masashi Mizokami

BONE MARROW TRANSPLANTATION (2020)

Add to Collection

Article Virology

Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation

Akihiro Tamori, Kiminori Kimura, Kiyohide Kioka, Hirayuki Enomoto, Naoshi Odagiri, Ritsuzo Kozuka, Sawako Uchida-Kobayashi, Masaru Enomoto, Norifumi Kawada, Masashi Mizokami

Summary: In this retrospective study of 133 patients undergoing NA therapy for hepatitis B virus reactivation, it was found that high levels of HBsAg at baseline and at the end of therapy were associated with relapse after cessation of NA treatment. In patients with resolved HBV, anti-HBs status could predict the need for NA therapy after reactivation.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety, tolerability, and anti-fibrotic efficacy of the CBP/I3-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study

Kiminori Kimura, Tatsuya Kanto, Shinji Shimoda, Kenichi Harada, Masamichi Kimura, Koji Nishikawa, Jun Imamura, Eiichi Ogawa, Masanao Saio, Yoshihiro Ikura, Takuji Okusaka, Kazuaki Inoue, Tetsuya Ishikawa, Ichiro Ieiri, Junji Kishimoto, Koji Todaka, Terumi Kamisawa

Summary: This study assessed the safety tolerability and anti-fibrotic effects of PRI-724 in patients with HCV-and HBV-induced cirrhosis. The results showed that PRI-724 did not significantly decrease hepatic fibrosis, but it improved liver stiffness, Model for End-stage Liver Disease score, and serum albumin level significantly.

EBIOMEDICINE (2022)

Add to Collection

Article Cell Biology

Phosphotungstic Acid-treated Picrosirius Red Staining Improves Whole-slide Quantitative Analysis of Collagen in Histological Specimens

Yui Mukade, Sayaka Kobayashi, Yoshimi Nishijima, Kiminori Kimura, Akira Watanabe, Hayato Ikota, Ken Shirabe, Hideaki Yokoo, Masanao Saio

Summary: This study attempted to prevent non-specific nuclear staining (NS-NS) of picrosirius red (PSR) staining by treating specimens with phosphotungstic acid (PTA). The results showed that PTA + PSR significantly suppressed NS-NS and had the highest correlation with the pathological evaluation of liver fibrosis. Additionally, the study found that non-polarized PSR-stained substances (NP-PSR+S) clinging to collagen fibers potentially explained the higher Sirius Red-positive percentage (SRP%) observed under PSR.

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2023)

Add to Collection

Article Infectious Diseases

Prevalence of hepatitis C virus infection among men who have sex with men with human immunodeficiency virus-1 infection between 2010 and 2020 in Japan: A single-center retrospective cohort study

Koji Nishikawa, Masamichi Kimura, Jun Imamura, Kiminori Kimura

Summary: This study investigates the prevalence of HCV infection among HIV-positive MSM in Japan. The results show a high prevalence of HCV infection in this population, and the treatment with direct-acting antivirals is highly effective.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease

Masamichi Kimura, Koji Nishikawa, Yosuke Osawa, Jun Imamura, Kenzaburo Yamaji, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Atsushi Tanaka, Tatsuya Kanto, Michinori Kohara, Terumi Kamisawa, Kiminori Kimura

Summary: The study found that the selective CBP/beta-catenin inhibitor PRI-724 can suppress cholestatic liver fibrosis by inhibiting bile acid synthesis and exerting anti-inflammatory effects in hepatocytes. The results also suggest that the Egr-1 gene plays an important role in bile acid synthesis and fibrosis, and the CBP/beta-catenin signaling pathway regulates Egr-1 expression.

HEPATOLOGY COMMUNICATIONS (2022)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

PRI-724, a Selective Inhibitor of Wnt/β-Catenin/CBP Signaling, Ameliomates Nash-Induced Liver Fibrosis

Kenzaburo Yamaji, Yuko Tokunaga, Takahiro Ohtsuki, Yosuke Osawa, Kiminori Kimura, Go Sugawara, Yuji Ishida, Chise Tateno, Yoichiro Hirose, Yukiko Hayashi, Tsunekazu Hishima, Michinori Kohara

HEPATOLOGY (2018)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Safety, tolerability, and anti-fibrotic effect of PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus cirrhosis: A single-center, open-label, dose escalation phase 1 trial

Masamichi Kimura, Koji Nishikawa, Jun Imamura, Keni-chi Harada, Masashi Mizokami, Kiminori Kimura

HEPATOLOGY (2017)

Add to Collection

Meeting Abstract Medicine, Research & Experimental

Inhibition of Cyclic Adenosine Monophosphate (cAMP)-Response Element-Binding Protein (CREB)-Binding Protein (CBP)/β-Catenin Directly Attenuates the Hepatocytes-Mediated Fibrogenesis

Yuki Mizutani, Kiminori Kimura, Hiroyuki Kouji, Hironori Koga, Kenichi Hrada

LABORATORY INVESTIGATION (2017)

Add to Collection

Article Gastroenterology & Hepatology

Tumor Necrosis Factor-alpha-Mediated Hepatocyte Apoptosis Stimulates Fibrosis in the Steatotic Liver in Mice

Yosuke Osawa, Ekumi Kojika, Yukiko Hayashi, Masamichi Kimura, Koji Nishikawa, Sachiyo Yoshio, Hiroyoshi Doi, Tatsuya Kanto, Kiminori Kimura

HEPATOLOGY COMMUNICATIONS (2018)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.